Skip to main content
Premium Trial:

Request an Annual Quote

Reel Two Acquires Gene-Searching Software from New Zealand Biotech

NEW YORK, April 11 (GenomeWeb News) - Biomedical text-mining firm Reel Two has acquired the rights to high-throughput gene searching technology that it developed for Genesis Research and Development, a therapeutic-development company based in New Zealand.


The software, called Cartesian, was written for in-house use at Genesis. The firms recently reached an agreement under which Reel Two owns the patents and gains the right to commercialize the software, while Genesis will be entitled to a share of the revenues.


"Reel Two has worked closely with Genesis to develop the Cartesian software and is the ideal party to take the product to market," said Stephen Hall, CEO of Genesis, in a statement.


According to Genesis, the Cartesian software has been designed to perform "very fast searching of genetic sequences." The company said that in internal use, the software "reduced analysis and computation time by many orders of magnitude, reducing tasks that had previously taken many months on a large computer cluster down to hours on a single machine."


Further financial terms of the agreement were not disclosed.


This article originally appeared in BioInform, a GenomeWeb News publication.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.